Abivax (NASDAQ:ABVX) Trading Up 6% – Time to Buy?

Abivax SA Sponsored ADR (NASDAQ:ABVX) shares shot up 6% on Wednesday . The stock traded as high as $148.83 and last traded at $146.6450. 422,088 shares were traded during mid-day trading, a decline of 52% from the average session volume of 880,521 shares. The stock had previously closed at $138.35.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ABVX shares. Wall Street Zen cut shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Truist Financial set a $140.00 target price on Abivax in a report on Monday, November 24th. Barclays began coverage on shares of Abivax in a report on Monday, October 13th. They issued an “overweight” rating and a $142.00 price target on the stock. JMP Securities boosted their price objective on shares of Abivax from $95.00 to $114.00 and gave the company a “market outperform” rating in a research note on Thursday, September 25th. Finally, Morgan Stanley upped their target price on shares of Abivax from $71.00 to $101.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Abivax presently has an average rating of “Moderate Buy” and an average price target of $128.73.

Abivax Price Performance

The firm’s 50-day moving average is $110.40 and its 200-day moving average is $74.15. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $11.39 billion, a PE ratio of -84.48 and a beta of 0.48.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million during the quarter. Equities analysts predict that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abivax

A number of hedge funds and other institutional investors have recently modified their holdings of ABVX. FNY Investment Advisers LLC purchased a new position in Abivax in the 3rd quarter worth approximately $275,000. Hudson Bay Capital Management LP purchased a new stake in Abivax during the 3rd quarter valued at $7,731,000. Tudor Investment Corp ET AL bought a new stake in Abivax in the 3rd quarter worth $2,792,000. Cantor Fitzgerald L. P. purchased a new position in shares of Abivax in the third quarter valued at about $2,972,000. Finally, Woodline Partners LP raised its stake in shares of Abivax by 69.2% during the third quarter. Woodline Partners LP now owns 311,042 shares of the company’s stock valued at $26,407,000 after acquiring an additional 127,242 shares during the last quarter. Institutional investors own 47.91% of the company’s stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.